Details of the Drug Combination

General Information of Drug Combination (ID: DCUUT8M)

Drug Combination Name
Flucytosine Fluconazole
Indication
Disease Entry Status REF
Cryptococcal Meningitis Phase 1 [1]
Component Drugs Flucytosine   DM13VTW Fluconazole   DMOWZ6B
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Flucytosine
Disease Entry ICD 11 Status REF
Cryptococcal meningitis N.A. Approved [2]
Endocarditis BB40-BA42 Approved [3]
Flucytosine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Candida Thymidylate synthase (Candi TMP1) TTU6BFZ TYSY_CANAL Inhibitor [3]
------------------------------------------------------------------------------------
Indication(s) of Fluconazole
Disease Entry ICD 11 Status REF
Cryptococcal meningitis N.A. Approved [4]
Fungal infection 1F29-1F2F Approved [5]
Invasive candidiasis 1F23 Approved [4]
Mycoses 1F2Z Approved [4]
Oral candidiasis 1F23.0 Approved [4]
Autoimmune polyendocrine syndrome type 1 N.A. Investigative [4]
Candidemia 1F23.3Y Investigative [4]
Esophageal candidiasis N.A. Investigative [4]
Fluconazole Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Candida Cytochrome P450 51 (Candi ERG11) TTTSOUD CP51_CANAL Modulator [7]
------------------------------------------------------------------------------------
Fluconazole Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [8]
------------------------------------------------------------------------------------
Fluconazole Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Steroidogenic acute regulatory protein, mitochondrial (STAR) OTFEZ5AI STAR_HUMAN Increases Expression [9]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases ADR [6]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Increases Metabolism [10]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01715922) Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa
2 Flucytosine FDA Label
3 Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9.
4 Fluconazole FDA Label
5 Fluconazole use as an important risk factor in the emergence of fluconazole-resistant Candida glabrata fungemia. Arch Intern Med. 2009 Aug 10;169(15):1444-5; author reply 1445.
6 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol. 2000 Jun;56(3):225-9.
9 Fluconazole inhibits human adrenocortical steroidogenesis in vitro. J Endocrinol. 2012 Dec;215(3):403-12. doi: 10.1530/JOE-12-0310. Epub 2012 Oct 4.
10 [Simultaneous determination of the inhibitory potency of compounds on the activity of five cytochrome P-450 enzymes using a cocktail probe substrates method]. Yao Xue Xue Bao. 2007 Jun;42(6):589-94.